Today, Access to COVID-19 Tools Accelerator published its consolidated investment case, with costing plans from member organizations.
Launched in late April 2020 at an event co-hosted by the Director General of the World Health Organization, President of France, President of the European Commission and The Bill and Melinda Gates Foundation, ACT-accelerator. Together governments, health organizations, scientists, businesses, civil society, and philanthropists have joined forces to end the epidemic.
Since the ACT-Accelerator was launched, partner organizations have steadily moved forward to develop cost and implementable plans designed to contribute to the end of the epidemic through accelerated growth, equal allocation, and death. Increased delivery of new equipment to reduce rates and critical. Disease, protecting health systems and restoring full social and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.
Act-accelerating investment case and costing schemes
Act-accelerator investment cases and & # 39; Pillars & # 39; The plans published by each of the major organizations show a path to accelerated development, equal allocation, and increased delivery of 500 million clinical trials by 245 million courses between 2021, LMIC, and treatment to LMIC by mid-2021 2 billion vaccine doses, 50% of which will go to LMIC by the end of 2021.
To achieve this, the cost plans presented today call for US $ 31.3 billion in funding for diagnostics, medicine and vaccines, of which US $ 3.4 billion has been loaned so far (2). An additional US $ 27.9 billion is required, of which US $ 13.7 billion is needed to cover the immediate needs (ie US $ 17.1 billion is the immediate need, of which US $ 3.4 billion is mortgaged).
The required investment is significant, but it becomes significant when compared to the cost of COVID-19: the total cost of the ACT-Accelerator work is less than one-tenth of the IMF's estimate that the global economy is suffering losses every month. Ubiquitous epidemic. 468,000 thousand people have already lost their lives.
Developed equipment will benefit the whole world; ACT-Accelerator poles will also purchase and distribute equipment to ensure LMIC access.
The investment case of Act-Accelerator is available here.
Act- Accelerator Pillar
The Act-Accelerator leads the work of collaborative organizations under four pillars.
The Diagnostics Pillar is led by FIND and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and aims to save 9 million lives and 1.6 billion further infections through the power of equal access to simple, accurate and inexpensive tests Have to avoid. With enough funding, it can market 2-3 high-quality rapid tests, train 10,000 healthcare professionals in 50 countries, and set up tests for 500 million people in low- and middle-income countries Can do. Its success will be determined by how quickly test, trace, and isolate strategies can be put in place to reduce health services disruption, and prepare countries for effective roll-out of once available therapeutics and vaccines do. The investment case is available here.
Therapeutics Pillar is led by UNITED and the Wellcome Trust (on behalf of COVID-19 Therapeutic Accelerator) and strives to accelerate the development and equitable delivery of treatments at all stages of the disease, ensuring that they cover geography Be accessible to everyone regardless. Level of economic resources. It targets the development, manufacture, procurement, and equitable distribution of 245 million courses of treatment for populations in low and middle income countries within 12 months. The investment case is available here.
The vaccine column combines CEPI's leadership in vaccine development and investment, revolutionizing access and delivery with GAVI's track record, and monitoring WHO's regulation, policy and allocation. Its role is to ensure that vaccines are rapidly developed, manufactured in the right quantities without compromising safety and delivered to the people they need most. The current estimate of 2 billion doses by the end of 2021, developed in the near future by assuming a safe and effective vaccine, is up to US $ 18.1 billion. In addition, 950 million doses will need to be purchased by self-financed high-income countries and upper middle-income countries through the COAXAX facility. Once we get a better idea, among other factors, the successful vaccine will be based on the number of doses needed for candidates and for the safety of people with COVID-19. The investment case is available here.
The Health System Connector is the fourth pillar of the ACT-accelerator and supports the other three to ensure that the health system and local community networks fully utilize these and other essential tools in their fight against COVID-19 Can. The column is led by the World Bank and the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and supported by WHO. Its purpose is to build capacity – such as laboratory capacity, training for laboratory and health workers, and management of protective equipment for health workers – when they are ready new equipment needs to be deployed effectively. It also works on systems innovation to complement the rollout of products, such as contact tracing, social distance and isolation approaches as well as those needed to maintain community engagement. The fight against global health protection and COVID-19 now depends on maintaining health systems worldwide.
call to action
Since its introduction, many governments and companies have indicated commitment and made financial pledges for the ACT-Accelerator. To date, the contributing countries have committed a total crime of US $ 3.4. The funding gap is US $ 27.9 billion.
On 27 June, at the Global Goal: Unite for Our Future, campaigns, concerts and summits, citizens will be called upon to use our collective voice to deal with global injustice for all, for change everywhere. World leaders, corporations and philanthropists will announce new commitments to help develop COVID-19 testing, treatment and equitable distribution of vaccines, as well as rebuilding communities devastated by the epidemic. Global citizens, the European Commission, united with top actors and global leaders to end COVID-19, build equity for all and fight for the world we want. Link: https://www.globalcitizen.org/en/connect/globalgoalunite/
Notes to editors
Access to the COVID-19 tool act-accelerator is a new, global collaboration to accelerate the development, production, and equitable access to COVID-19 diagnostics, therapeutics and vaccines. It was established in March in response to a call from G20 leaders and was launched in April 2020 by WHO, EC, France and The Bill & Melinda Gates Foundation.
Act-accelerators are not a decision-making body or a new organization, but serve to intensify collaborative efforts between existing organizations to end the epidemic. It is a framework for collaboration that is designed to bring key players around the table to accelerate the epidemic by reducing COVID-19 mortality and critical illness through accelerated growth, equitable allocation and scaled distribution To be finished as soon as possible. Vaccines, therapies and diagnostics, which protect the health system and restore societies and economies in the near term. It draws on the experience of leading global health organizations that are tackling the world's toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to defeat COVID-19 and ensure access to all the means necessary to work with unprecedented levels of partnership to achieve it.
ACT-Accelerator has four areas of work: diagnosis, medicine, vaccines and health system connectors. Cross-cutting all of these is a workstream at access and allocation.
(1) For health systems An additional billion dollars have been spent.
(2) The time limit for vaccine poles is 18 months.
For more information, please visit ACT accelerator.